Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

10/19/2021 | 08:03am EST

Item 8.01 Other Events.

On October 19, 2021, Sage Therapeutics, Inc. issued a press release titled "Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022." A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by Sage Therapeutics, Inc. on October 19, 2021.


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SAGE THERAPEUTICS, INC.
01/10SAGE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/06Needham Adjusts Sage Therapeutics Price Target to $85 From $79, Reiterates Buy Rating
MT
01/04Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tu..
BU
2021SVB Leerink Adjusts Sage Therapeutics PT to $60 From $70, Maintains Market Perform Rati..
MT
2021Sage Therapeutics Third Annual FutureCast Showcases Data from All Three Brain Health Fr..
AQ
2021Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health F..
BU
2021Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Developm..
AQ
2021Sage Therapeutics, Biogen Report Positive Data From Antidepressant Drug Candidate Zuran..
MT
2021SAGE THERAPEUTICS : and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the On..
PU
2021SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations